Arcturus Therapeutics Announces Extraordinary General

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
559
Arcturus Therapeutics Announces Extraordinary General Meeting of Shareholders

Board of Directors Recommends Removal of Terminated CEO Joseph Payne from Board of Directors

SAN DIEGO, May 21, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (Arcturus or the Company) (NASDAQ: ARCT ), an RNA medicines company, today announced that it will hold an extraordinary general meeting of shareholders, or the EGM, on Monday, June 25, 2018 at 10 a.m. Pacific time at the offices of Arcturus’ U.S. legal counsel, Cooley LLP, located at 4401 Eastgate Mall, San Diego, California, 92121-1909, at which the shareholders will vote on two sets of competing proposals. Proposals 1, 2 and 3 were proposed by a shareholder, director, and former chief executive officer, Joseph Payne, who was terminated for cause, pursuant to his demand for the shareholders meeting under Israeli law. Proposal 4 is being proposed by the Arcturus board of directors.  The proposals for consideration by the shareholders are as follows:

Proposals Recommended by Joseph Payne (Proposals 1-3)

Proposal 1 : Approval of the following resolution:

Resolution 1 : To remove and transfer, Messrs. Stuart Collinson, Craig Willett, Daniel Geffken and David Shapiro - as well as any other person that may be appointed to the Board pursuant to article 4.2.3 of the Articles of Association of the Company, as of the date hereof and until the EGM, including the four persons the Board may have resolved to appoint at its meeting of April 20, 2018 - from the office of directors on the Board.  Such termination to be with immediate effect, so that until additional directors are appointed pursuant to resolution 3 below, only Mr. Joseph Payne will remain as director on the Board.

Proposal 2: Approval of the following resolution:

Resolution 2 : To amend articles 4.2.1 and 4.2.2 of the Articles of Association of the Company, with immediate effect, so that the authority to determine the number of directors of the Company, as well as the authority to elect new directors to the Board is also provided – in any circumstances - to extraordinary general meetings of the shareholders of the Company. The proposed amendments to these articles shall come into effect upon the approval of this resolution by the EGM, and are as follows (proposed changes are underlined):

“4.2.1 The number of Directors of the Company shall be determined from time to time by the Annual Meeting or an Extraordinary Meeting , provided that this shall not be fewer than 5 and not more than 11 Directors, including External Directors.  The number of External Directors in the Company shall not be less than the number determined in the Companies Law.”

“4.2.2 Other than External Directors (who shall be elected and serve in office in strict accordance with the provisions of the Companies Law), the Directors in the Company shall be elected at an Annual Meeting or at an Extraordinary Meeting and shall serve in their office until the next Annual Meeting following one year from their election, or until they cease to serve in their office in accordance with the provisions of the Articles or any law, whichever is the earlier.”

Proposal 3 : Approval of the following resolution:

Resolution 3 : Further to the approval of resolution 2 of the agenda, or if not approved than pursuant to article 4.2.11 to the Articles of Association of the Company, to elect the following four individuals to serve as directors on the Board, effective immediately following the EGM’s approval: (a) Mr. Peter Farrell; (b) Mr. Andrew Sassine; (c) Mrs. Magda Marquet; (d) Mr. James Barlow.

Proposal Recommended by Arcturus’ Board of Directors (Proposal 4)

Proposal 4 :  Approval of the following resolution:

Resolution 4 : To remove Mr. Joseph Payne from his role as a Director on Arcturus’ Board, with immediate effect.

Arcturus is currently not aware of any other matters that will come before the meeting. If any other matters are presented properly at the meeting, the persons designated as proxies intend to vote upon such matters in accordance with their best judgment. Wednesday, June 6, 2018, will serve as the record date of shareholders entitled to vote at the EGM.

Arcturus’ Board of Directors Recommends that Arcturus’ Shareholders Vote “FOR” Proposal 4 and “AGAINST” Proposals 1, 2 and 3.

Further Details Concerning the EGM

The presence in person or by proxy of two or more shareholders possessing at least one-third (1/3) of Arcturus’ voting rights will constitute a quorum at the shareholders meeting. In the absence of a quorum within one hour of the scheduled time for the meeting, the meeting will be adjourned for one week and will be held on Monday, July 2, 2018 at the same time and place, unless Arcturus otherwise informs its shareholders. At such adjourned meeting, the presence of at least two shareholders in person or by proxy (regardless of the voting rights possessed by their shares) will constitute a quorum. Approval of each proposal at the meeting (or any adjournment thereof) requires the affirmative vote of a majority of the ordinary shares present (in person or by proxy) and voting thereon (which excludes abstentions and broker non-votes).

Registered holders who are unable to attend the meeting in person will be requested to complete, date and sign their proxy cards and return them promptly in the pre-addressed envelope that will be provided, so as to be received not later than 11:59 PM, Eastern time, on Sunday, June 24, 2018. No postage will be required if a proxy card is mailed in the United States to Arcturus’ U.S. transfer agent, Continental Stock Transfer & Trust Company. Shareholders who attend the meeting in person may revoke their proxies and vote their ordinary shares at the meeting.  Shareholders whose ordinary shares in Arcturus are held in “street name” (i.e., through a bank, broker or other nominee) will be able to either direct the registered record holder of their shares on how to vote such shares or obtain a legal proxy from the registered record holder to enable such “street name” holder to participate in and to vote such shares at the meeting (or to appoint a proxy to do so). An earlier deadline may apply to receipt of such “street name” shareholders’ voting instruction forms.

The Board urges you to return the proxy card or voting instruction form to be sent to you by the Board in order to vote FOR Proposal 4 and AGAINST Proposals 1 through 3.

About Arcturus Therapeutics Ltd.

Founded in 2013 and based in San Diego, Arcturus Therapeutics Ltd. (NASDAQ: ARCT ) is an RNA medicines company with enabling technologies – UNA Oligomer chemistry and LUNAR ® lipid-mediated delivery. Arcturus' diverse pipeline of RNA therapeutics includes programs pursuing rare diseases, Hepatitis B, non-alcoholic steatohepatitis (NASH), cystic fibrosis, and vaccines. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of RNA medicines including small interfering RNA, messenger RNA, replicon RNA, antisense RNA, microRNA and gene editing therapeutics. Arcturus owns LUNAR lipid-mediated delivery and Unlocked Nucleomonomer Agent (UNA) technology including UNA Oligomers, which are covered by its extensive patent portfolio (120 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries). Arcturus’ proprietary UNA technology can be used to target individual genes in the human genome, as well as viral genes, and other species for therapeutic purposes. Arcturus’ commitment to the development of novel RNA therapeutics has led to partnerships with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, Synthetic Genomics Inc., CureVac AG and Cystic Fibrosis Foundation Therapeutics Inc. For more information, visit  www.ArcturusRx.com , the content of which is not incorporated herein by reference.

Additional Information and Where to Find It

In connection with the meeting, Arcturus will make available to its shareholders of record a proxy statement describing the time and place for, and other logistical information related to, the meeting, information regarding the identity of the participants, and their director or indirect interests, by security holdings or otherwise, and describing the proposals to be voted upon at the meeting, along with a WHITE proxy card enabling them to submit their votes on that proposal. Arcturus will also be furnishing copies of the proxy statement and WHITE proxy card to the United States Securities and Exchange Commission, or the SEC, in a Report of Foreign Private Issuer on Form 6-K, which may be obtained for free from the SEC’s website at www.sec.gov and will be available on Arcturus’ website at http://ir.arcturusrx.com/ . SHAREHOLDERS OF ARCTURUS ARE STRONGLY ENCOURAGED TO READ SUCH PROXY STATEMENT, ACCOMPANYING WHITE PROXY CARD AND ALL OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE AS THEY WILL CONTAIN IMPORTANT INFORMATION.  Arcturus and certain of its directors and executive officers are expected to be participants in the solicitation of proxies from Arcturus’ shareholders in connection with the EGM. 

The full text of the proposed resolutions for the meeting, together with the Board’s form of WHITE proxy card, may also be viewed beginning on Thursday, June 7, 2018, at the registered office of Arcturus, c/o Meitar Liquornik Geva Leshem Tal, 16 Abba Hillel Road, Ramat Gan, Israel 5250608, 12 th Floor, from Sunday to Thursday (excluding holidays), 10:00 a.m. to 5:00 p.m. (Israel time).  Arcturus’ telephone number at its registered office is +972-3-610-3157.    Forward-Looking Statements

This press release may contain “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, included in this press release regarding strategy, future operations, collaborations, future financial position, prospects, plans and objectives of management are forward-looking statements. Examples of such statements may include, but are not limited to, statements relating to the expectations regarding solicitation of proxies and voting by Arcturus’ shareholders. Arcturus may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in any forward-looking statements and you should not place undue reliance on those forward-looking statements. Any such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in any forward-looking statements.

The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in Arcturus’ (formerly Alcobra Ltd.’s) Annual Report on Form 20-F for the fiscal year ended December 31, 2017, filed with the SEC on May 14, 2018 and in subsequent filings with, or submissions to, the SEC. Except as otherwise required by law, Arcturus disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

Media Contacts Arcturus Therapeutics +1 (858) 900-2660 info@arcturusRx.com

Investor Contacts Michael Wood LifeSci Advisors LLC +1 (646) 597-6979 mwood@lifesciadvisors.com

Mike Verrechia Morrow Sodali, LLC (212) 300-2476 ARCT@morrowsodali.com

Andrew Brimmer / Trevor Gibbons Joele Frank, Wilkinson Brimmer Katcher (212) 355-4449

Scroll down for more posts ▼

Top 10 Most Recent News Articles

DemandTec Leads the Pack in Retail Pricing Arena

Updated Category News Views 114

DemandTec's Climb to Retail Pricing Stardom The news hitting the streets is that DemandTec's carved out a top spot in QKS Group's SPARK Matrix™ for Intelligent Retail Pricing & Promotion Optimization for 2026. In an industry filled with slick operators and gimmicks, it takes some real chops to stand out. They've clinched this position by rolling out a platform that ties...

Continue Reading
Surgical Tooth Extraction: When It’s Necessary

Updated Category News Views 98

Unpacking the Complexities of Tooth Extraction Ever wonder why some tooth extractions are a stroll in the park while others dive straight into surgical territory? It's all about positioning, condition, and what's lurking underneath. Thanks to Dr. Yadira Cardona-Rohena of Hamilton Mill Oral & Facial Surgery, we’ve got the lowdown. The Need for Skilled Surgical Techniques...

Continue Reading
Teamsters Ratify Contract, Averting Waste Strike

Updated Category News Views 55

Big Win for Teamsters Local 350 You ever seen a strike averted by sheer willpower and unity? That’s what's happened here with the workers at South San Francisco Scavenger Company. These folks—drivers, mechanics, sorters, and utility workers—all banded together under the Teamsters Local 350 and showed management what's what by securing a contract they deserve. We're...

Continue Reading
Christian Faith: Navigating Spiritual Pitfalls Wisely

Updated Category News Views 126

Taking a Deep Look at Christian Faith If you think faith is as simple as saying a few prayers and checking church attendance off the list, well, think again. G. Joseph Johnson, in his thought-provoking tome "Roads, Ditches, Traps, and Snares," believes that faith is a journey filled with twists, turns, and yes, a few traps. This book is a sort of roadmap for Christians,...

Continue Reading
Dr. Obeng Joins WellcomeMD with Special Offer for Patients

Updated Category News Views 47

New Beginnings in Concierge Medicine In late October, WellcomeMD opened its doors to Dr. Paa-Kofi Obeng—an arrival greeted with considerable anticipation in Richmond's medical scene. This isn't just any run-of-the-mill staff addition; Dr. Obeng brings with him over a decade of experience from places like the Veterans Administration Medical Center. He's armed with a...

Continue Reading
Tigo Energy Faces Lawsuit: Key Details for Investors

Updated Category News Views 89

Tigo Energy Inc.'s Troubles: A Stock Drop and Legal Woes You see, not every day do you wake up to find your investment taking a nose dive by 36.76%. But that’s exactly what happened to Tigo Energy, Inc. (NASDAQ: TYGO) after some shaky announcements. A Rollercoaster for Investors On August 4, 2026, Tigo hit investors with a one-two punch: revised financial outlook and...

Continue Reading
Galileo's Robot Dog Takes Charge in Polish Warehouses

Updated Category News Views 179

Robotic Innovation Makes Waves in Europe You ever think you’d see the day when a dog—albeit a robotic one—takes the night shift at a warehouse? Well, here we are. Galileo Robotics has unleashed its C1-W robot dog in Poznan, Poland, and it's more than just a fancy tech gimmick. This thing's got potential, bridging gaps left wide open by human labor shortages and...

Continue Reading
Dawson Struggles With Q3 Losses Despite Growth Prospects

Updated Category News Views 110

Profit and loss dance around like a jittery stock, and Dawson Geophysical is feeling the heat this third quarter. Numbers are in, and we’re seeing a net loss of $5.2 million, translating to $0.17 per share—ouch. Not to mention a negative Adjusted EBITDA of $2 million. Compared to last year's hopes, that's a serious belly flop. Revenue Down, Hopes Up In a fetching...

Continue Reading
Flagship's £100M London Move to Ignite AI Ventures

Updated Category News Views 253

London Calling: Flagship's New Venture Flagship Pioneering, the brain behind bustling biotech ventures like Moderna, is planting its flag in London. They're launching Flagship Origination Lab, U.K., their first real gig outside good ol' Cambridge, Massachusetts. They're diving in headfirst, sprinkling a whopping £100 million to brew up AI-native platform companies. And...

Continue Reading
DHL Leverages Robust Growth in Resilient Supply Chains

Updated Category News Views 104

Supply Chain Resilience: A Strategic Game Changer Market volatility's got its teeth in the game, and everyone in logistics knows it. DHL Supply Chain isn't just sitting back; they're riding the wave of change, snagging a 12% revenue bump in 2026. It's not your typical headline growth, either. More like the kind of growth that gets logistics gurus eyeing those contract...

Continue Reading

Top 5 Most Recently Viewed Articles

Highlights and Expectations for AAR's Upcoming Earnings Call

Updated Category News Views 102

AAR's Upcoming Earnings Release AAR (NYSE:AIR) is set to unveil its quarterly earnings report soon. Investors keenly await this announcement, hoping for positive surprises both in earnings and guidance for the future. Analysts’ Earnings Expectations Analysts predict that AAR will post an earnings per share (EPS) of $1.03. This figure reflects the optimism surrounding...

Continue Reading
Tradeweb Markets Reports Significant Trading Volume Growth

Updated Category News Views 218

Tradeweb Markets Sees Record Trading Volume in January Tradeweb Markets Inc. (NASDAQ: TW), a premier global provider of electronic marketplaces for trading various financial instruments, reported a phenomenal total trading volume of $54.6 trillion for January 2025. This figure represents an average daily volume (ADV) of approximately $2.44 trillion, showcasing a robust...

Continue Reading
Cal Water Celebrates EPA Recognition for Water Efficiency Efforts

Updated Category News Views 73

California Water Service, trading under NYSE: CWT, scored a big win back in 2024 when it snagged the U. S. Environmental Protection Agency’s (EPA) WaterSense Excellence in Promoting WaterSense Labeled Products Award for the second consecutive year. This ain't just fluff; it reflects a serious commitment to pushing water-efficient solutions that resonate with their...

Continue Reading
Navigating Market Trends: Key Earnings Week Insights

Updated Category News Views 125

Market Trends Before Earnings As we enter a pivotal earnings week, investors are feeling the pressure as tech stocks have led the way downwards. This anticipated decline comes as many anticipate significant corporate earnings that could either uplift or hamper the current record-setting rally in the markets. Stock Performance and Investor Sentiment On this busy Monday...

Continue Reading
Revolutionizing Insurance Research: The Game-Changer ZORRO Discover

Updated Category News Views 145

Introduction to ZORRO Discover ZestyAI has unveiled a groundbreaking tool aimed at transforming the insurance industry: ZORRO Discover. This innovative generative AI agent is set to revolutionize the way insurers handle regulatory filings and competitive market analysis, potentially reshaping operational strategies across the board. Significance of ZORRO Discover...

Continue Reading